Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

被引：2

作者：

Parrondo, Ricardo D. ^{[1
]}

Laplant, Betsy R. ^{[2
]}

Elliott, Jamie ^{[1
]}

Fernandez, Andre ^{[1
]}

Flott, Caitlin J. ^{[1
]}

Arrington, Diedre ^{[1
]}

Chapin, Dustin ^{[1
]}

Brown, Jade ^{[1
]}

Das, Saurav ^{[1
]}

Roy, Vivek ^{[1
]}

Chanan-Khan, Asher A. ^{[1
,3
]}

Ailawadhi, Sikander ^{[1
,3
]}

机构：

[1] Mayo Clin, Canc Ctr, Dept Hematol Oncol, Jacksonville, FL 32224 USA

[2] Mayo Clin, Quantitat Hlth Sci, Rochester, MN USA

[3] Mayo Clin, Ctr Canc, Dept Canc Biol, Jacksonville, FL 32224 USA

来源：

BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期

关键词：

D O I：

10.1038/s41408-024-01134-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：5

共 50 条

[21] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
David S. Siegel
Gary J. Schiller
Christy Samaras
Michael Sebag
Jesus Berdeja
Siddhartha Ganguly
Jeffrey Matous
Kevin Song
Christopher S. Seet
Giampaolo Talamo
Mirelis Acosta-Rivera
Michael Bar
Donald Quick
Bertrand Anz
Gustavo Fonseca
Donna Reece
William E. Pierceall
Weiyuan Chung
Faiza Zafar
Amit Agarwal
Nizar J. Bahlis
Leukemia, 2020, 34 : 3286 - 3297
[22] Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
Siegel, David S.
Schiller, Gary J.
Samaras, Christy
Sebag, Michael
Berdeja, Jesus
Ganguly, Siddhartha
Matous, Jeffrey
Song, Kevin
Seet, Christopher S.
Talamo, Giampaolo
Acosta-Rivera, Mirelis
Bar, Michael
Quick, Donald
Anz, Bertrand
Fonseca, Gustavo
Reece, Donna
Pierceall, William E.
Chung, Weiyuan
Zafar, Faiza
Agarwal, Amit
Bahlis, Nizar J.
LEUKEMIA, 2020, 34 (12) : 3286 - 3297
[23] Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Amrita Krishnan
Prashant Kapoor
Joycelynne M. Palmer
Ni-Chun Tsai
Shaji Kumar
Sagar Lonial
Myo Htut
Chatchada Karanes
Nitya Nathwani
Michael Rosenzweig
Firoozeh Sahebi
George Somlo
Lupe Duarte
James F. Sanchez
Daniel Auclair
Stephen J. Forman
Jesus G. Berdeja
Leukemia, 2018, 32 : 1567 - 1574
[24] Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma
Krishnan, Amrita
Kapoor, Prashant
Palmer, Joycelynne M.
Tsai, Ni-Chun
Kumar, Shaji
Lonial, Sagar
Htut, Myo
Karanes, Chatchada
Nathwani, Nitya
Rosenzweig, Michael
Sahebi, Firoozeh
Somlo, George
Duarte, Lupe
Sanchez, James F.
Auclair, Daniel
Forman, Stephen J.
Berdeja, Jesus G.
LEUKEMIA, 2018, 32 (07) : 1567 - 1574
[25] Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study
Martino, Enrica Antonia
Derudas, Daniele
Rossi, Elena
Stefanoni, Paola
Mangiacavalli, Silvia
Zamagni, Elena
Offidani, Massimo
Furlan, Anna
Quinto, Angela Maria
Della Pepa, Roberta
Bertuglia, Giuseppe
Barbieri, Emiliano
Conticello, Concetta
De Magistris, Claudio
Bongarzoni, Velia
Cafro, Anna Maria
Mele, Anna
Botta, Cirino
Sgherza, Nicola
Mele, Giuseppe
Annibali, Ombretta
Rago, Angela
Fontana, Raffaele
Vigna, Ernesto
Bruzzese, Antonella
Mancuso, Katia
Amendola, Angela
Citro, Annalisa
Cotzia, Emilia
More, Sonia
Rivolti, Elena
Pettine, Loredana
Galli, Monica
De Stefano, Valerio
Petrucci, Maria Teresa
Corso, Alessandro
Neri, Antonino
Di Raimondo, Francesco
Bolli, Niccolo
Musto, Pellegrino
Morabito, Fortunato
Gentile, Massimo
HEMATOLOGICAL ONCOLOGY, 2025, 43 (02)
[26] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
San Miguel, Jesus
Raab, Marc S.
Goldschmidt, Hartmut
Lonial, Sagar
Richardson, Paul G.
Shelat, Suresh
Bleickardt, Eric W.
Palumbo, Antonio
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
Yashar, David
Spektor, Tanya M.
Martinez, Daisy
Ghermezi, Matthew
Swift, Regina A.
Eades, Benjamin
Schwartz, Gary
Eshaghian, Shahrooz
Lim, Stephen
Vescio, Robert
Berenson, James R.
LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 975 - 983
[28] A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients
Berenson, James
Martinez, Daisy
Spektor, Tanya
Sanchez, Armando
Ghermezi, Matthew
Swift, Regina
Eades, Benjamin
Schwartz, Gary
Eshaghian, Shahrooz
Lim, Stephen
Vescio, Robert
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E249 - E250
[29] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone (DIPD) As Salvage Therapy in Early Relapsed/Refractory Multiple Myeloma
Kumar, Anupama
Rosenberg, Aaron S.
Ball, Edward D.
Larson, Sarah M.
Sirianni, Lindsey
Mulroney, Carolyn M.
Costello, Caitlin L.
BLOOD, 2023, 142
[30] Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial
Dimopoulos, Meletios A.
Dytfeld, Dominik
Grosicki, Sebastian
Moreau, Philippe
Takezako, Naoki
Hori, Mitsuo
Leleu, Xavier
LeBlanc, Richard
Suzuki, Kenshi
Raab, Marc S.
Richardson, Paul G.
McKiver, Mihaela Popa
Jou, Ying-Ming
Yao, David
Das, Prianka
San-Miguel, Jesus
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 568 - +

← 1 2 3 4 5 →